Rocket Lab USA, Inc. RKLB Issuance of common stock warrants in connection with Loan Agreement

Issuance of common stock warrants in connection with Loan Agreement at other companies

ADMA BiologicsADMA

$1.4M—

KEE

Keel Infrastructure Corp. Common StockKEEL

$2.15M—

NextNavNN

-$2.25M—

Kestra Medical Technologies, Ltd. Common StockKMTS

$1.36M—

KEE

Keel Infrastructure Corp. Common StockKEEL

$11.48M—

Ondas, Inc. ONDS

$549.75K—

Other financials

Income statement

See full

Revenue$200.3M+63.5%

Gross profit$76.5M+117%

Operating income-$56.0M+5.4%

Net income-$45.0M+25.7%

EPS (diluted)-$0.07+41.7%

Balance sheet

See full

Cash & equivalents$1.2B+293%

Total debt$101.8M-29.2%

Total equity$2.3B+425%

Total assets$2.8B+125%

Cash flow

See full

Operating cash flow-$50.3M+7.2%

CapEx$27.1M-5.6%

Free cash flow-$77.4M+6.6%

Valuation

See full

Market cap$50.42B+264%

Enterprise value$49.31B+260%

P/S74.2×+44.4×

Profitability

See full

Gross margin36.6%+9.3pp

Operating margin-33.2%-6.6pp

Net margin-26.9%-7.6pp

FCF margin-46.5%+13.5pp

Returns & leverage

See full

Return on equity-13.5%-5.6pp

Debt / equity0×-0.3×

Current ratio4.5×+2.4×

Where this comes from

Reported directly by Rocket Lab USA, Inc. in its filing.

Tagged under the XBRL concept rklb:IssuanceOfCommonStockWarrantsAndAccruedIssuanceCostsConnectionWithLoanAndSecurityAgreement.

The official record: Rocket Lab USA, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rocket Lab USA, Inc.'s issuance of common stock warrants in connection with loan agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rocket Lab USA, Inc.'s issuance of common stock warrants in connection with loan agreement?: Rocket Lab USA, Inc. (RKLB) reported issuance of common stock warrants in connection with loan agreement of $0 in Q4 2025.
What does issuance of common stock warrants in connection with loan agreement mean?: This metric tracks the issuance of equity warrants as part of financing arrangements, typically as a sweetener for debt. It represents a potential future dilution of shareholder value in exchange for current capital access.